DUOPHARMA BIOTECH BERHAD
Malaysia | 7148.KL | Main
Reference
Report Year: 2023
Source Files: Duopharma_Biotech_-_Integrated_Annual_Report_2023_-_PART_1.pdf, Duopharma_Biotech_-_Integrated_Annual_Report_2023_-_PART_2.pdf, Duopharma_Biotech_-_Sustainability_Report_2023.pdf
Sustainability Committee
Halal and Sustainability Committee 🟢
- 5 meetings 🟢
- Reviewed NZTP 🟢
- Monitored ESG ratings 🟢
Reporting
GRI, TCFD, Separate Report 🟢
GHG Accounting
Duopharma Biotech demonstrates a structured approach to GHG accounting with a focus on Scope 1, 2, and partial Scope 3 emissions (covering waste, business travel, and commuting). The report highlights a verified carbon intensity of 56.28 tCO₂e/RM million revenue, a slight reduction from 2022, showcasing incremental progress. Third-party verification by Carbon Check (India) Pvt. Ltd. adds credibility. However, absolute emission figures for Scopes 1 and 2 are not specified, limiting transparency. Scope 3 reporting, while initiated, remains incomplete. The company aims for carbon neutrality by 2030 and net zero by 2050, supported by a Net Zero Transition Plan. Improvements could include detailed absolute data for all scopes and broader Scope 3 coverage to enhance accountability.
Emissions
| Scope | Value | Note |
|---|---|---|
| Scope1 | Data not specified ⚠️ | Absolute figures for Scope 1 not detailed in report. |
| Scope2 | Data not specified ⚠️ | Absolute figures for Scope 2 not detailed in report. |
| Scope3 | Partial data (3 categories) 🟢 | Covers waste, business travel, employee commuting. |
| Biogenic emissions | Not applicable → | No biomass or biofuel usage reported. |
Other Details
- Base year: 2022 for Scope 3 categories
- Boundary inventory: Operations in Malaysia, Singapore, Indonesia, Philippines
- Gwp basis: Not specified
- Standard: GHG Protocol (implied)
- Data collection approach: Internal tracking and reporting
- Third party verification: Verified by Carbon Check (India) Pvt. Ltd.
- Carbon intensity: 56.28 tCO₂e/RM million revenue, verified 🟢
Efforts
- Reduced intensity 🟢
- 12,000 RECs 🟢
- Recycling initiatives 🟢
- Solar panels (2,558 kWp) 🌞
- Biodegradable packaging 🌱
Social Highlights
- RM1.60M training 🟢
- 1,940 employees supported 🟢
- Mental health programs 🥗
- Limited data available ⚠️
- Limited data available ⚠️
Governance
- Salary disclosure: Can't find ⚠️
- Litigation: Can't find ⚠️
Report Quality
Commendable effort by Duopharma Biotech in producing a detailed sustainability report for 2023 🟢. The report excels in providing a structured framework with clear alignment to GRI and TCFD standards, supported by third-party verification of key metrics like carbon intensity. Quantifiable actions, such as the installation of solar panels (2,558 kWp) and purchase of 12,000 RECs, demonstrate tangible environmental commitment. Forward-looking goals like carbon neutrality by 2030 and net zero by 2050 are ambitious and well-articulated. However, the report falls short in presenting absolute GHG emission data for Scopes 1 and 2, which limits transparency ⚠️. Social impact metrics are present but lack depth in measurable outcomes beyond training and employee support. To improve, the company should include comprehensive emission figures and enhance social impact reporting with specific, verifiable results. Overall, a solid foundation that could benefit from greater detail and specificity.
Tags:
Looking for ESG Strategy & Improvement?
Disclaimer:
This is AI model generated summary based on certain rules set by Sustify.world perspective. If the reader finds the information is incorrect, they can always approach us by sending email admin@sustify.world.
Need Expert help?
Contact us TODAY for sustainability strategy, reporting, and outsourcing services.